Covidien Prevails in Patent Action Against Applied Medical Resources
NEW HAVEN, Conn.--(BUSINESS WIRE)-- Covidien (NYS: COV) , a global healthcare products company, announced that it has prevailed against Applied Medical Resources, Inc. in a patent action before the United States Court of Appeals for the Federal Circuit.
In May 2011, Applied Medical sued Covidien in connection with Covidien's sale of certain trocar products. On August 27, the United States Court of Appeals for the Federal Circuit affirmed the lower court's previous ruling that Covidien's trocar products do not infringe Applied Medical's patent.
This is the fifth patent infringement action since 2000 that Applied Medical has brought against Covidien (and its predecessor companies) relating to trocars seals. Covidien has secured dismissal of all five of these actions.
"We are pleased the Court recognized that Covidien's trocar products are differentiated from our competitors. As we have demonstrated, we will vigorously protect our innovative products, solutions and intellectual property," stated Steve Blazejewski, President of Surgical Supplies, Covidien.
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading products in medical devices and supplies. With 2012 revenue of $9.9 billion, Covidien has 38,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.
John Jordan, 508-452-4891
Coleman Lannum, CFA, 508-452-4343
Vice President, Investor Relations
Marguerite Copel, 203-821-4720
Vice President, Communications
Todd Carpenter, 508-452-4363
Senior Director, Investor Relations
KEYWORDS: United States North America Connecticut
The article Covidien Prevails in Patent Action Against Applied Medical Resources originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.